Your search returned 719 results.

Results
	441.	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. [electronic resource] by Miyawaki, Masayoshi Yasuda, Hiroyuki Tani, Tetsuo Hamamoto, Junko Arai, Daisuke Ishioka, Kota Ohgino, Keiko Nukaga, Shigenari Hirano, Toshiyuki Kawada, Ichiro Naoki, Katsuhiko Hayashi, Yuichiro Betsuyaku, Tomoko Soejima, Kenzo Producer: 20170811 In: Molecular cancer research : MCR vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	442.	Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. [electronic resource] by Wu, Ting-Hui Hsiue, Emily Han-Chung Lee, Jih-Hsiang Lin, Chia-Chi Liao, Wei-Yu Ho, Chao-Chi Shih, Jin-Yuan Yu, Chong-Jen Yang, James Chih-Hsin Producer: 20190308 In: Clinical lung cancer vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	443.	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. [electronic resource] by Hasegawa, Hanako Yasuda, Hiroyuki Hamamoto, Junko Masuzawa, Keita Tani, Tetsuo Nukaga, Shigenari Hirano, Toshiyuki Kobayashi, Keigo Manabe, Tadashi Terai, Hideki Ikemura, Shinnosuke Kawada, Ichiro Naoki, Katsuhiko Soejima, Kenzo Producer: 20191227 In: Lung cancer (Amsterdam, Netherlands) vol. 127 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	444.	MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells. [electronic resource] by Ebert, Karolin Mattes, Julian Kunzke, Thomas Zwingenberger, Gwen Luber, Birgit Producer: 20200402 In: PloS one vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	445.	Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. [electronic resource] by Geater, Sarayut L Xu, Chong-Rui Zhou, Caicun Hu, Cheng-Ping Feng, Jifeng Lu, Shun Huang, Yunchao Li, Wei Hou, Mei Shi, Jian Hua Lee, Kye Young Palmer, Michael Shi, Yang Lungershausen, Juliane Wu, Yi-Long Producer: 20160405 In: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	446.	Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. [electronic resource] by Macha, Muzafar A Rachagani, Satyanarayana Qazi, Asif Khurshid Jahan, Rahat Gupta, Suprit Patel, Anery Seshacharyulu, Parthasarathy Lin, Chi Li, Sicong Wang, Shuo Verma, Vivek Kishida, Shosei Kishida, Michiko Nakamura, Norifumi Kibe, Toshiro Lydiatt, William M Smith, Russell B Ganti, Apar K Jones, Dwight T Batra, Surinder K Jain, Maneesh Producer: 20171013 In: Oncotarget vol. 8 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	447.	Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. [electronic resource] by Hong, Shu-Ting Lin, Huaching Wang, Chen-Shen Chang, Chih-Hsien Lin, Anya Maan-Yuh Yang, James Chih-Hsin Lo, Yu-Li Producer: 20200204 In: Journal of nanobiotechnology vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	448.	Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. [electronic resource] by Hiret, Sandrine Isambert, Nicolas Gomez-Roca, Carlos Bennouna, Jaafar Sassi, Mouna de Mont-Serrat, Hélène Fan, Jean Schnell, David Delord, Jean-Pierre Producer: 20190610 In: Investigational new drugs vol. 36 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	449.	Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. [electronic resource] by Weaver, Zoë Difilippantonio, Simone Carretero, Julian Martin, Philip L El Meskini, Rajaa Iacovelli, Anthony J Gumprecht, Michelle Kulaga, Alan Guerin, Theresa Schlomer, Jerome Baran, Maureen Kozlov, Serguei McCann, Thomas Mena, Salvador Al-Shahrour, Fatima Alexander, Danny Wong, Kwok-Kin Van Dyke, Terry Producer: 20130305 In: Cancer research vol. 72 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	450.	Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. [electronic resource] by Freiwald, Matthias Schmid, Ulrike Fleury, Angele Wind, Sven Stopfer, Peter Staab, Alexander Producer: 20140715 In: Cancer chemotherapy and pharmacology vol. 73 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	451.	Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. [electronic resource] by Suzawa, Ken Toyooka, Shinichi Sakaguchi, Masakiyo Morita, Mizuki Yamamoto, Hiromasa Tomida, Shuta Ohtsuka, Tomoaki Watanabe, Mototsugu Hashida, Shinsuke Maki, Yuho Soh, Junichi Asano, Hiroaki Tsukuda, Kazunori Miyoshi, Shinichiro Producer: 20160613 In: Cancer science vol. 107 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	452.	Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity. [electronic resource] by Toba, Hiroaki Sakiyama, Shoji Takizawa, Hiromitsu Tangoku, Akira Producer: 20170130 In: The journal of medical investigation : JMI vol. 63 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	453.	Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. [electronic resource] by Jakubowski, Christopher D Plodkowski, Andrew J Chang, Jason C Rekhtman, Natasha Iqbal, Afsheen Paik, Paul K Yu, Helena A Producer: 20181001 In: Clinical lung cancer vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	454.	Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. [electronic resource] by Cohen, E E W Licitra, L F Burtness, B Fayette, J Gauler, T Clement, P M Grau, J J Del Campo, J M Mailliez, A Haddad, R I Vermorken, J B Tahara, M Guigay, J Geoffrois, L Merlano, M C Dupuis, N Krämer, N Cong, X J Gibson, N Solca, F Ehrnrooth, E Machiels, J-P H Producer: 20180529 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	455.	Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells. [electronic resource] by Yonesaka, Kimio Kobayashi, Yoshihisa Hayashi, Hidetoshi Chiba, Yasutaka Mitsudomi, Tetsuya Nakagawa, Kazuhiko Producer: 20190204 In: Oncology reports vol. 41 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	456.	Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. [electronic resource] by Lim, Jonathan Samuelsen, Carl Golembesky, Amanda Shrestha, Sulena Wang, Li Griebsch, Ingolf Producer: 20190909 In: Future oncology (London, England) vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	457.	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. [electronic resource] by Haddad, Robert Guigay, Joel Keilholz, Ulrich Clement, Paul M Fayette, Jérôme de Souza Viana, Luciano Rolland, Frédéric Cupissol, Didier Geoffrois, Lionnel Kornek, Gabriela Licitra, Lisa Melichar, Bohuslav Ribaldo Nicolau, Ulisses Rauch, Daniel Zanetta-Devauges, Sylvie Cohen, Ezra E W Machiels, Jean-Pascal Tahara, Makoto Vermorken, Jan Geng, Yuan Zografos, Eleftherios Gauler, Thomas Producer: 20200630 In: Oral oncology vol. 97 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	458.	Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. [electronic resource] by Westerink, Lotte Nicolai, Jelmer L J Samuelsen, Carl Smit, Hans J M Postmus, Pieter E Griebsch, Ingolf Postma, Maarten J Producer: 20210616 In: The European journal of health economics : HEPAC : health economics in prevention and care vol. 21 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	459.	Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis. [electronic resource] by Lin, Chou-Han Lin, Ming-Tzer Kuo, Yao-Wen Ho, Chao-Chi Producer: 20150511 In: Lung cancer (Amsterdam, Netherlands) vol. 85 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	460.	Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. [electronic resource] by Schuler, Martin Fischer, Jürgen R Grohé, Christian Gütz, Sylvia Thomas, Michael Kimmich, Martin Schneider, Claus-Peter Laack, Eckart Märten, Angela Producer: 20151214 In: The oncologist vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

First
Previous
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
Next
Last

Refine your search

Availability

Authors

Topics

Languages

Your search returned 719 results.